Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

生物製剤の世界市場2018-2028:タンパク質治療薬、モノクローナル抗体、融合タンパク質、再生医療、インスリン、その他の組み換えホルモン、血漿・組み換え凝固因子、インターフェロン、酵素補充、幹細胞療法、組織工学製品、遺伝子治療

◆タイトル:Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies
◆商品コード:VGN902103
◆調査・発行会社:visiongain
◆発行日:2018年11月
◆ページ数:303
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle UserGBP3,499 ⇒換算¥507,355見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算¥565,355見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算¥724,855見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"生物製剤の世界市場2018-2028:タンパク質治療薬、モノクローナル抗体、融合タンパク質、再生医療、インスリン、その他の組み換えホルモン、血漿・組み換え凝固因子、インターフェロン、酵素補充、幹細胞療法、組織工学製品、遺伝子治療"について調査・分析し、レポートサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、セグメント別市場分析、市場環境分析、結論などの情報をお届けいたします。

The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 303-page report you will receive 166 charts– all unavailable elsewhere.

The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Biologics Market outlook from 2018-2028

• Global Biologics Submarkets analysis and forecast from 2018-2028:
• Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
• Vaccines

• Analysis and forecast from 2018-2028 for selected leading biologics in the market:
• Lantus
• NovoLog/NovoRapid
• Humalog
• Avonex
• Rebif
• Humira
• Remicade
• Tysabri
• Herceptin
• Kadcyla
• Perjeta
• Enbrel
• Eylea
• OsteoCel Plus
• Trinity Evolution and Trinity Elite
• Apligraf
• Dermagraft
• IMLYGIC

• This report provides individual revenue forecasts from 2018-2028 for these national markets:
• The US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• India
• Russia
• Brazil

【レポートの目次】

1. Report Overview
1.1 Biologics Overview
1.2 Why you Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Market Dynamics

2.1 Drivers
2.1.1 Increasing Biologics Approvals
2.1.2. Rise in the Prevalence of Chronic Diseases
2.2 Restraints
2.2.1 Complex in Nature
2.2.2 High Cost
2.3 Opportunities
2.3.1 Strong Pipeline of biologics drugs
2.3.2 Emerging technology
2.4 Trends
2.4.1 Growing strategic partnerships in China
2.4.2 Outsourcing strategies

3. Introduction to the Biologics Market and Key Concepts
3.1 Biologics: Large and Complex Products
3.2 A Brief History of Biological Drug Development
3.3 Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
3.4 What are Biosimilars?
3.4.1 Brief History of Biosimilars
3.4.2 What are Interchangeable Biological Products and how do They Differ from Biosimilars?
3.4.3 Why Many Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars
3.5 Marginal Cases
3.6 Vaccines Market

4. The Global Biologics Market 2018 – 2028
4.1 The Global Biologics Market 2018 – 2028
4.2 What Factors Will Drive Growth in the Biologics Market?
4.2.1 Ageing Population and the Rise of Chronic Disease
4.2.2 Biologics Constitute 19% of the Global Pharmaceutical Market – Further Launches Will Drive Market
4.3 Biosimilars – Both an Opportunity and a Threat
4.4 What Factors Will Restrain Growth in the Biologics Market?
4.4.1 High Costs in the Face of Declining National Healthcare Budgets
4.4.2 In Some Areas, Clinical Efficacy is not Superior Enough to Justify the Price Gap
4.4.3 Over $100bn worth of Biologic Patents due to Expire by 2020
4.4.4 Administration is Often not as Convenient
4.5 Biologics Market: Submarket Forecasts 2018 – 2028

5. Protein Therapeutics Submarket 2018 – 2028
5.1 Largest and Most Diverse Submarket
5.2 Proteins have been used Medicinally since the 19th Century
5.2.1 Recombinant DNA Technology – The Major Breakthrough in the use of Protein Drugs
5.3 Protein Therapeutics Submarket Forecast 2018 – 2028
5.4 Insulin Submarket 2018 – 2028
5.4.1 The First Protein Therapeutic
5.4.2 Around 430 Million People Expected to be Diagnosed with Diabetes by 2030
5.4.3 Insulin Submarket Forecast 2018 – 2028
5.4.4 Lantus: The Market Leading Drug by Far
5.4.4.1 Lantus Revenue Forecast 2018 – 2028
5.4.5 NovoLog/NovoRapid Revenue Forecast to 2028
5.4.6 Humalog Revenue Forecast to 2028
5.4.7 New Approvals and Pipeline
5.4.7.1 Tresiba (Novo Nordisk)
5.4.7.2 BIOD-123 (Biodel)
5.5 Biosimilar Insulin
5.5.1 Approved Insulin Biosimilars
5.5.2 Abasaglar/Basaglar/Insulin Glargine BS – The First Insulin Biosimilars to be Approved in Developed Markets. Delayed in the US
5.6 Other Recombinant Hormones: Erythropoietins, G-CSF and Human Growth Hormone
5.6.1 Erythropoietin
5.6.1.1 First-Generation Therapies Launched in the 1980s
5.6.1.2 Aranesp: Slowly Growing
5.6.1.3 Epogen: Increases in Selling Price are No Longer Enough to Ward off Decline
5.6.1.4 Procrit/Eprex: In Decline Since 2013
5.6.1.5 NeoRecormon and Mircera (Roche) Provides Competition for Market Leader Amgen
5.6.1.6 Safety Concerns for Erythropoietin-Stimulating Agents is Leading to Decreased Demand
5.6.1.7 The Challenge from Oral Therapies is Coming
5.6.1.8 Treating Anaemia in Patients with CKD – The Leading Use of EPO Therapies
5.6.1.9 Many Biosimilar Epoetins Approved Around the World
5.6.2 G-CSF
5.6.2.1 G-CSF: Discovered 1983. Recombinant Forms Available Since 1991
5.6.2.2 Amgen Leads the Market
5.6.2.3 Neupogen and Neulasta Revenues, and the Onpro Kit
5.6.2.4 Teva Aiming to Challenge Amgen’s Dominance
5.6.2.5 Facing Much Biosimilar Competition Around the World
5.6.3 Human Growth Hormone
5.6.3.1 Human Growth Hormone: First Extracted in 1958
5.6.3.2 Novo Nordisk Dominates Market
5.6.3.3 Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
5.6.3.4 Multiple Biosimilars Available – Omnitrope is Market Leader
5.6.3.5 Biosimilar Growth Hormones in Asia
5.6.4 Other Recombinant Hormones Submarket Forecast to 2028
5.7 Plasma and Recombinant Coagulating Factors
5.7.1 Types of Recombinant Factor
5.7.2 Clotting Factor Deficiency Diseases
5.7.3 Baxter/Baxalta: Entered the Bleeding Disorders Market in 1992, Markets Various Leading Products
5.7.3.1 Baxter: New Product Launches Include Rixubis and Obizur
5.7.4 Novo Nordisk: Committed to Remaining a Leading Company in the Bleeding Disorders Market
5.7.4.1 Novo Nordisk: Has filed for Approval for N9-GP and NovoEight is Doing Well
5.7.5 Bayer: Markets Kogenate, Kogenate FS, and has Received FDA Approval for Kovaltry
5.7.6 Limited Opportunities for Biosimilar Challenge
5.7.7 Plasma and Recombinant Coagulating Factors Submarket Forecast 2018 – 2028
5.8 Interferons
5.8.1 Interferons: Key Antiviral and MS Therapies Since the 1990s
5.8.2 Interferons for Treating Hepatitis: Its Influence is Decreasing
5.8.3 Competition from Oral Protease and Polymerase Inhibitors
5.8.3.1 Oral Therapies are Expensive
5.8.4 Avonex: The Leading Interferon Therapy
5.8.4.1 Avonex Revenue Forecast 2018 – 2028
5.8.5 Rebif: Merck Attempting to Differentiate Rebif from Other Interferon Therapies
5.8.5.1 Rebif Revenue Forecast 2018 – 2028
5.8.6 Betaseron
5.8.7 Plegridy: New Therapy with High Potential
5.8.8 Biosimilar Interferons: None Approved in Developed Markets, but Many Available in Emerging Nations
5.8.9 Interferon Submarket Forecast 2018 – 2028
5.9 Enzyme Replacement and Other Protein Therapies Submarket
5.9.1 Cerezyme: Genzyme’s Leading Enzyme Replacement Therapy
5.9.2 Myozyme and Lumizyme
5.9.3 Fabrazyme and Aldurazyme
5.9.4 Botulinum Toxin Brands Include Botox, Dysport and Xeomin
5.9.5 Other Protein Therapeutics Pipeline
5.9.5.1 Anthera Buys Sollpura from Eli Lilly, Phase 3 Results Expected Q4 2016
5.9.5.2 Multikine (CEL-SCI)
5.9.5.3 Vonapantiase (Proteon Therapeutics)
5.9.6 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast 2018 – 2028

6. Monoclonal Antibodies Submarket 2018 – 2028
6.1 Monoclonal Antibodies Submarket: Scientific and Historical Background
6.1.1 Natural Antibodies: Key to the Immune System
6.1.2 From Serum Therapy to Monoclonal Antibodies
6.1.3 Humanising the mAb
6.1.4 MAbs have found Success in Treating Autoimmune Disorders, Cancers and Others Diseases – Great Potential for the Future
6.1.5 MAbs for All? Technologies Come Off Patent
6.2 Autoimmune mAbs
6.2.1 Past Approvals
6.2.2 Humira – The World’s Best-Selling Prescription Drug
6.2.2.1 AbbVie Plans to Drive Growth Through New Indications
6.2.2.2 Positive Opinion from CHMP for Treatment of Non-Infectious Uveitis
6.2.2.3 Recently Approved for Hidradenitis Suppurativa in the US, Europe, and Japan
6.2.2.4 Biosimilar Adalimumab: Patents Protect Humira in Developed Markets for Now
6.2.2.5 Humira Revenue Forecast 2018 – 2028
6.2.3 Remicade: Second Only to Humira
6.2.3.1 Has Defended Revenues Well but Now Has to Deal with Biosimilar Competition
6.2.3.2 Patent Dance in US
6.2.3.3 Biosimilar Infliximab: Multiple Launches
6.2.3.4 Remicade Revenue Forecast 2018 – 2028
6.2.4 Stelara: Blockbuster Status Well Established
6.2.4.1 Stelara Revenues 2015-2017
6.2.4.2 Orphan Drug Designation for paediatric Crohn’s Disease
6.2.5 Tysabri: Blockbuster Drug’s High Efficacy Offsets its Risks
6.2.5.1 Tysabri Revenue Forecast 2018 – 2028
6.2.6 Xolair: New Indication, and Revenue Breakdown
6.2.7 Actemra/RoActemra: Strong Growth in All Regions
6.2.8 Cimzia: Blockbuster Which has been Used by Over 90,000 Patients
6.2.9 Autoimmune mAbs Pipeline: RA is the Main Target
6.2.9.1 Sarilumab (REGN88/SAR153191) by Regeneron and Sanofi: BLA Accepted for Review and Decision Expected by November 2016
6.2.9.2 Sirukumab (CNTO-136) by J&J and GSK: Multiple Phase 3 Studies Around the World
6.2.9.3 Clazakizumab: Developed by Alder Biopharmaceuticals and BMS but now Licensed to Vitaeris
6.2.9.4 Tregalizumab (BT-061) by Biotest: AbbVie Backs out After Poor Results
6.2.9.5 Mavrilimumab by AstraZeneca: Approaching Phase 3
6.2.9.6 Zinbryta (daclizumab high-yield process) by Biogen and AbbVie: Positive Opinion from CHMP
6.2.9.7 Lebrikizumab by Roche: Undergoing Phase 3 After Positive Phase 2b Results
6.2.9.8 Sifalimumab (MEDI-545) by AstraZeneca: Hasn’t Made the Cut for Phase 3
6.2.9.9 Anifrolumab by AstraZeneca
6.3 Oncology mAbs
6.3.1 Past Approvals
6.3.2 Rising Incidence of Cancer Will Drive Demand
6.3.3 Rituxan: The World’s Leading Anti-Cancer mAb
6.3.4 Biosimilar Rituximab: Two Candidates Await Approval in Europe
6.3.5 Gazyva: Roche’s Successor to Rituxan, Will Help to Retain Revenues in Face of Biosimilar Competition
6.3.5.1 Approval for Follicular Lymphoma and Being Investigated for Other Indications
6.3.6 Avastin: Growing under CER, Through New Indications
6.3.6.1 Controversy over Off-Label Avastin use: Roche is Backed up by Incidents in India, and Opinion of EFPIA
6.3.6.2 Biosimilar Bevacizumab: Late Patent Expiry is a Blessing for Roche, Although Various Biosimilars in Development
6.3.7 Herceptin: Breast Cancer Blockbuster
6.3.7.1 Pricing Challenges in Emerging Markets, and 2016 Revenues
6.3.7.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
6.3.7.3 Herceptin Revenue Forecast 2018 – 2028
6.3.7.4 Biosimilar Trastuzumab
6.3.8 Kadcyla
6.3.8.1 Mixed Results from Different Clinical Trials
6.3.8.2 Kadcyla Sales Forecast 2018 -2028
6.3.9 Perjeta
6.3.9.1 Positive Results from Different Clinical Trials
6.3.9.2 Perjeta Revenue Forecast 2018 – 2028
6.3.10 Yervoy: Bristol-Myers Squibb’s Leading Anti-Cancer mAb, KeepsHigh Revenues, but with Decline over 2015
6.3.11 Opdivo: Big Potential for Bristol-Myer Squibb’s PD-1 Inhibitor
6.3.11.1 Good News and Bad News for NSCLC from CheckMate Trials
6.3.11.2 Cyramza (Eli Lilly): Approved in Three Additional Indications Since its First Approval in April 2014
6.3.12 Oncology mAbs: New Approvals and Pipeline
6.3.12.1 Empliciti (Elotuzumab) by Bristol-Myers Squibb and AbbVie): Recently Approved
6.3.12.2 Avelumab: Pfizer and Merck KGaA Team Up to Develop Their Own Anti-PD mAb
6.3.12.3 Unituxin (United Therapeutics) Receives FDA Approval March 2015
6.3.12.4 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
6.4 Monoclonal Antibodies Submarket Forecast 2018 – 2028

7. Fusion Proteins Submarket 2018 – 2028
7.1 Scientific and Historical Background
7.2 Differentiating Fusion Proteins
7.3 Enbrel: The First FP to be Approved, in 1998
7.3.1 Gradually Approved for Additional Indications
7.3.2 Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
7.3.3 Multiple Biosimilars Available in Emerging Markets
7.3.4 Enbrel Revenue Forecast 2018 – 2028
7.4 Eylea: Blockbuster FP Treatment for Wet AMD
7.4.1 Eylea Revenue Forecast 2018 – 2028
7.5 Orencia: Grows Blockbuster Revenues for Second Year in a Row
7.6 Nplate: Generates Half a Billion in Revenues for Amgen
7.7 Eloctate: Approved June 2014, Fulfils Unmet Need in the Haemophilia Community
7.8 Nulojix: Bristol-Myers Squibb’s Therapy for Preventing Organ Rejection
7.9 Arcalyst by Regeneron Pharmaceuticals: For Very Rare Conditions
7.10 Fusion Proteins Pipeline
7.10.1 Trebananib (Amgen)
7.10.2 Sotatercept by Acceleron Pharma and Celgene Corporation – Currently Undergoing Eight Clinical Trials
7.10.3 Blisibimod (Anthera Pharmaceuticals) for the Treatment of Various Autoimmune Diseases, in Late Stage Development
7.11 Fusion Protein Submarket Forecast to 2018 – 2028

8. Regenerative Medicines Submarket 2018 – 2028
8.1 Regenerative Medicines Market Breakdown
8.2 Regenerative Medicines Submarket Forecast, 2018 – 2028
8.3 Stem Cell Therapies Submarket, 2018 – 2028
8.3.1 Stem Cells: Scientific Breakdown
8.3.2 Stem Cell Therapies Submarket Breakdown
8.3.3 Haematopoietic Stem Cell Transplantation: Over 95,000 Carried out in 2016
8.3.3.1 From Procedures to Products: Cord Blood Stem Cell Approvals
8.3.4 Osteocel Plus: The Leading Stem Cell Orthobiologic
8.3.4.1 Osteocel Plus Revenue Forecast 2018 – 2028
8.3.5 Trinity Evolution and Trinity Elite
8.3.5.1 Trinity Evolution and Trinity Elite Revenue Forecast to 2028
8.3.6 MSC-100-IV (Previously Known as Prochymal): World’s First Approved Stem Cell Drug Outside of South Korea
8.3.6.1 An Important Role to Play in the Future of HSCT, and also Wins Approval in Japan through Partner
8.3.7 CARTISTEM (MEDIPOST): The World’s First Allogeneic Stem Cell Drug
8.3.8 Hearticellgram-AMI (PharmaCell B.V.): One of the First Approved Cardiovascular Stem Cell Treatments in the World
8.3.9 Stem Cell Therapies Pipeline
8.3.9.1 Cx601 by TiGenix: Marketing Authorisation Application has been Submitted to EMA
8.3.9.2 CardiAMP (BioCardia) for Heart Failure: Undergoing Phase 3 Trial and has Received Grant from MSCRF
8.3.9.3 NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS in Phase 2 and Due to end Soon
8.3.9.4 Agenmestencel-T (Apceth): Phase 1/2 Due to end Soon
8.3.10 Stem Cell Therapies Submarket Forecast 2018 – 2028
8.4 Tissue Engineering Therapies Submarket 2018 – 2028
8.4.1 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes
8.4.2 Current Status of the Market
8.4.3 Apligraf: The Leading Product
8.4.3.1 Apligraf Revenue Forecast 2018 – 2028
8.4.4 Dermagraft: Organogenesis Further Strengthens Position Through this 2014 Acquisition
8.4.4.1 Dermagraft Revenue Forecast 2018 – 2028
8.4.5 ReCell
8.4.6 MySkin and CyroSkin
8.4.7 Tissue Engineering Therapies Pipeline
8.4.7.1 NeoCart by Histogenics: Undergoing Phase 3 Trial for Knee Cartilage Repair
8.4.7.2 Extracorporeal Bio-Artificial Liver Therapy by Vital Therapies
8.4.7.3 StrataGraft by Stratatech Corporation Demonstrates Positive Top-Line Results
8.5 Gene Therapies Submarket 2018 – 2028
8.5.1 Gene Therapy: Historical and Scientific Background
8.5.2 Harnessing Infectivity: Viral Vectors in Gene Therapy
8.5.3 Approved Gene Therapy Products
8.5.3.1 Gendicine: The World’s First Commercial Gene Therapy Product
8.5.3.2 Oncorine: First Oncolytic Viral Therapy
8.5.3.3 Neovasculgen: Russia’s First Gene Therapy
8.5.3.4 Neovasculgen: Drop in Revenues in 2015, but HSCI Predicts Notable Increases as Product is Added to VED List
8.5.3.5 Glybera: The First Gene Therapy for Western Markets, Although Has Abandoned Hope of Receiving FDA-Approval
8.5.4 IMLYGIC
8.5.4.1 IMLYGIC: Clinical Trials and Development Efforts
8.5.4.2 IMLYGIC: Revenue Forecast 2018 – 2028
8.5.5 Gene Therapies Pipeline
8.5.5.1 AAV2-hRPE65v2 (Spark Therapeutics): Undergoing Phase 3 Trial
8.5.5.2 AdV-tk/ProstAtak (Advantagene): Phase 3
8.5.5.3 Collategene (beperminogene perplasmid, AMG0001) – (AnGes MG/Vical)

9. Leading National Markets for Biologics 2018 – 2028
9.1 Regional Forecasts for the Global Biologics Market to 2028
9.2 US Biologics Market 2018 – 2028
9.2.1 The Major National Market
9.2.2 Value-Based Pricing in the US
9.2.3 Regulation of Biologics in the US
9.2.4 US Biosimilars Market
9.2.4.1 FDA Finalises Biosimilar Guidelines and Biosimilar Naming
9.2.5 US Biologics Market Forecast 2018 – 2028
9.3 EU5 Biologics Market 2018 – 2028
9.3.1 Current Composition and Future Outlook
9.3.2 European Biosimilar Market
9.3.2.1 History of EMA Guidelines and Updates
9.3.3 EU5 Market Forecast by Nation 2018 – 2028
9.4 Japanese Biologics Market 2018 – 2028
9.4.1 Current Status of the Japanese Biologics Market
9.4.2 Japanese Biosimilar Market
9.4.3 Japanese Biologics Market Forecast 2018 – 2028
9.5 BRIC National Biologic Markets 2018 – 2028
9.5.1 BRIC Markets Overview
9.5.2 BRIC Biologic Market Forecast 2018 – 2028
9.5.2.1 Unique Challenges Faced by the Biologics Industry have led to Current Composition of the BRIC Biologic Market
9.5.2.2 Future Outlook
9.5.2.3 BRIC Nation Market Shares in the Global Biologics Market Will Nearly Double During the Forecast Period
9.5.3 Brazil: Disproportionately High Government Spending on Biologics
9.5.3.1 Brazilian Government Eager to Promote Domestic Biologic and Biosimilar Development
9.5.4 Russia: Another Government Which is Eager to Increase Domestic Biological Drug Development
9.5.5 India: Biologics Market Behind that of Other BRIC Nations, but Biosimilars Submarket Thriving
9.5.5.1 CDSCO Guidelines Released in 2012
9.5.6 China: Expected to be the Largest BRIC Market for Biologics by 2020
9.5.6.1 The Largest National Biosimilar Market in the World

10. Qualitative Analysis of the Biologics Market and Industry
10.1 SWOT Analysis of the Global Biologics Market and Industry
10.1.1 Strengths
10.1.2 Opportunities
10.1.3 Weaknesses
10.1.4 Threats
10.2 STEP Analysis of the Global Biologics Market and Industry
10.2.1 Social Factors
10.2.2 Technological Developments
10.2.3 Economic Pressures
10.2.4 Political Issues

11. Company Profiles
11.1 AbbVie Inc.: Profile
11.1.1 AbbVie Inc.: Company Overview
11.2 Amgen: Profile
11.2.1 Amgen: Company Overview
11.3 AstraZeneca PLC: Profile
11.3.1 AstraZeneca PLC: Company Profile
11.4 Bayer AG: Profile
11.4.1 Bayer AG: Profile
11.5 Eli Lilly: Profile
11.5.1 Eli Lilly: Company Overview
11.6 F. Hoffmann-La Roche Ltd.: Profile
11.6.1 F. Hoffmann-La Roche Ltd.: Company Overview
11.7 GlaxoSmithKline Plc.: Profile
11.7.1 GlaxoSmithKline Plc.: Company Overview
11.8 Johnson & Johnson Services, Inc.: Profile
11.8.1 Johnson & Johnson Services, Inc.: Company Overview
11.9 Merck & Co., Inc.: Profile
11.9.1 Merck & Co., Inc.: Company Overview
11.10 Novartis AG: Profile
11.10.1 Novartis AG: Profile
11.11 Pfizer Inc.: Profile
11.11.1 Pfizer Inc.: Company Overview
11.12 Sanofi S.A.: Profile
11.12.1 Sanofi S.A: Company Overview

12. Conclusions
12.1 Biologics Market to Achieve Steady Growth Throughout the Forecast Period
12.2 Changes in Market Composition: mAbs to Become Leading Submarket
12.3 The Emergence of Biosimilars
12.4 Challenges for the Market

Appendices
Visiongain Report Sales Order Form
Associated Visiongain Reports
About Visiongain
Visiongain report evaluation form

List of Tables
Table 3.1 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 4.1 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 4.2 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
Table 4.3 Patent Status of Selected Leading Biologics
Table 4.4 Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 4.5 Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2028
Table 5.1 First Approvals for Recombinant Protein Therapies,1982-1993
Table 5.2 Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.3 Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
Table 5.4 Diabetes Prevalence in Leading National Markets, 2017
Table 5.5 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.6 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
Table 5.7 Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.8 Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
Table 5.9 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.10 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
Table 5.11 Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2018-2023
Table 5.12 Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
Table 5.13 Selected Insulin Biosimilars which have been Approved and Launched
Table 5.14 Selected EPO Biosimilars Approved in India
Table 5.15 European Biosimilar Approvals: G-CSF
Table 5.16 Selected Filgrastim Biosimilars Approved Worldwide, 2016
Table 5.17 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.18 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2028
Table 5.19 Selected Coagulating Factors Significant in Segment
Table 5.20 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.21 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
Table 5.22 Selected Approved Branded Interferon Therapies
Table 5.23 Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.24 Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), to 2028
Table 5.25 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2023
Table 5.26 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2023-2028
Table 5.27 Selected Interferon Alfa Biosimilars Approved Worldwide, 2016-2017
Table 5.28 Selected Interferon Beta Biosimilars Approved Worldwide, 2016-2017
Table 5.29 Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.30 Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
Table 5.31 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
Table 5.32 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
Table 6.1 Regions of an Antibody
Table 6.2 Natural Antibody Mechanisms of Action
Table 6.3 Selected Biosimilar Adalimumab Candidates
Table 6.4 Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 6.5 Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 6.6 Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 6.7 Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
Table 6.8 Stelara Revenue 2015-2017:
Revenues ($bn), AGR (%)
Table 6.9 Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 6.10 Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 6.11 Xolair Revenue Breakdown (between Roche and Novartis): Revenue ($bn), AGR (%), 2016-2017
Table 6.12 Selected Ongoing Lebrikizumab Clinical Trials
Table 6.13 Selected Ongoing Anifrolumab Clinical Trials
Table 6.14 Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2018-2023
Table 6.15 Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
Table 6.16 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2018-2023
Table 6.17 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
Table 6.18 Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 6.19 Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 6.20 FDA-Approved Indications for Cyramza
Table 6.21 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 6.22 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 7.1 Amgen’s US Patents and Expiry Dates for Enbrel
Table 7.2 Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 7.3 Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
Table 7.4 Eylea Revenue Breakdown 2016-2017: Regeneron and Bayer
Table 7.5 Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 7.6 Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 7.7 Bristol-Myers Squibb’s pipeline developments for Orencia
Table 7.8 Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 7.9 Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 8.1 Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 8.2 Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 8.3 Potency and Source of Stem Cells
Table 8.4 Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 8.5 Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 8.6 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2023
Table 8.7 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2023-2028
Table 8.8 Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 8.9 Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 8.10 Apligraf Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 8.11 Apligraf Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 8.12 Dermagraft Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 8.13 Dermagraft Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
Table 8.14 IMLYGICRevenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
Table 8.15 IMLYGICRevenue Forecast: Revenue ($bn), AGR (%), CAGR (%),
2023-2028
Table 9.1 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 9.2 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2028
Table 9.3 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2018-2023
Table 9.4 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2023-2028
Table 9.5 European Biosimilar Approvals, 2006-2017
Table 9.6 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2018-2023
Table 9.7 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2023-2028
Table 9.8 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2018-2023
Table 9.9 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2023-2028
Table 9.10 BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2018-2023
Table 9.11 BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2023-2028
Table 11.1 AbbVie, Inc.: Profile
Table 11.2 AbbVie, Inc.: Key Developments
Table 11.3 Amgen: Profile
Table
Table 11.4 Amgen: Key Developments
Table 11.5 AstraZeneca PLC: Profile
Table 11.6 AstraZeneca PLC: Key Developments
Table 11.7 Bayer AG: Profile
Table 11.8 Eli Lilly: Profile
Table 11.9 Eli Lilly: Key Developments
Table 11.10 Roche: Profile
Table 11.11 Roche: Key Developments
Table 11.12 GSK: Profile
Table 11.13 Johnson & Johnson: Profile
Table 11.14 Johnson & Johnson: Profile
Table 11.15 Merck & Co., Inc.: Profile
Table 11.16 Merck & Co., Inc.: Key Developments
Table 11.17 Novartis: Profile
Table 11.18 Novartis: Key Developments
Table 11.19 Pfizer: Profile
Table 11.20 Pfizer: Key Developments
Table 11.21 Sanofi: Profile
Table 11.22 Sanofi: Key Developments

List of Figures
Figure 1.1 Forecasted Submarkets of the Biologics Market
Figure 4.1 Global Biologics Market Forecast: Revenues ($bn), 2018 – 2028
Figure 4.2 Submarkets within the Biologics Market Forecast: Revenues ($bn),2017-2028
Figure 5.1 Protein Therapeutics Submarket Forecast: Revenues ($bn), 2018 – 2028
Figure 5.2 Diabetes Prevalence in Leading National Markets, 2017
Figure 5.3 Insulin Submarket Forecast: Revenues ($bn), 2018 – 2028
Figure 5.4 Lantus Revenue Forecast: Revenues ($bn), 2018 – 2028
Figure 5.5 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), 2018 – 2028
Figure 5.6 Humalog Revenue Forecast: Revenues ($bn), 2018 – 2028
Figure 5.7 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), 2018 – 2028
Figure 5.8 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), 2018 – 2028
Figure 5.9 Avonex Submarket Forecast: Revenues ($bn), 2018 – 2028
Figure 5.10 Rebif Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 5.11 Interferon Submarket Forecast: Revenues ($bn), 2018 – 2028
Figure 5.12 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), 2018 – 2028
Figure 6.1 Humira Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 6.2 Remicade Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 6.3 Stelara Revenue 2015-2017, Revenue ($bn)
Figure 6.4 Tysabri Revenue Forecast: Revenue ($m), 2018 – 2028
Figure 6.5 Herceptin Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 6.6 Kadcyla Revenue Forecast: Revenue ($m), 2018 -2028
Figure 6.7 Perjeta Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 6.8 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), 2018 – 2028
Figure 7.1 Enbrel Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 7.2 Eylea Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 7.3 Fusion Proteins Forecast: Revenue ($bn), 2018 – 2028
Figure 8.1 Regenerative Medicines Market Forecast: Revenue ($bn), 2018 – 2028
Figure 8.2 Osteocel Plus Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 8.3 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), 2018 – 2028
Figure 8.4 Stem Cell Therapies Market Forecast: Revenue ($bn), 2018 – 2028
Figure 8.5 Apligraf Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 8.6 Dermagraft Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 8.7 IMLYGIC Revenue Forecast: Revenue ($bn), 2018 – 2028
Figure 9.1 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2017
Figure 9.2 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2028
Figure 9.3 Regional Forecasts for Global Biologics Market: Revenues ($bn),to 2028
Figure 9.4 US Biologics Market: Revenues ($bn), 2018 – 2028
Figure 9.5 EU5 Market Breakdown: Market Share (%), 2017
Figure 9.6 EU5 Biologics Market: Revenues ($bn), 2018 – 2028
Figure 9.7 Japanese Biologics Market: Revenues ($bn), 2018 – 2028
Figure 9.8 Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2017
Figure 9.9 BRIC Biologics Market: Revenues ($bn), 2018 – 2028
Figure 9.10 Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2028
Figure 10.1 SWOT Analysis of Biologics Market and Industry
Figure 10.2 STEP Analysis of Biologics Market and Industry
Figure 12.1 Global Biologics Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2018 – 2028



★調査レポート[生物製剤の世界市場2018-2028:タンパク質治療薬、モノクローナル抗体、融合タンパク質、再生医療、インスリン、その他の組み換えホルモン、血漿・組み換え凝固因子、インターフェロン、酵素補充、幹細胞療法、組織工学製品、遺伝子治療] ( Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies / VGN902103) 販売に関する免責事項
[生物製剤の世界市場2018-2028:タンパク質治療薬、モノクローナル抗体、融合タンパク質、再生医療、インスリン、その他の組み換えホルモン、血漿・組み換え凝固因子、インターフェロン、酵素補充、幹細胞療法、組織工学製品、遺伝子治療] ( Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies / VGN902103) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆